Response to 'Comment on ''Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy"'

Amir Ansaripour; Carin Uyl - de Groot; Ken Redekop

doi:10.1007/s40273-018-0620-y

Response to 'Comment on ''Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy"'

Amir Ansaripour, Carin Uyl - de Groot, Ken Redekop

Health Technology Assessment (HTA)

Research output: Contribution to journal › Article › Academic › peer-review

30 Downloads (Pure)

Original language	English
Pages (from-to)	381-382
Number of pages	2
Journal	Pharmacoeconomics (Print)
Volume	36
Issue number	3
DOIs	https://doi.org/10.1007/s40273-018-0620-y
Publication status	Published - 2018

Research programs

EMC NIHES-05-63-02 Quality

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s40273-018-0620-y

10.1007_s40273-018-0620-y.pdfFinal published version, 599 KB

http://hdl.handle.net/1765/104709

Cite this

@article{1c47b9180212495d968b9190cf63c0c5,

title = "Response to 'Comment on ''Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy{"}'",

author = "Amir Ansaripour and {Uyl - de Groot}, Carin and Ken Redekop",

year = "2018",

doi = "10.1007/s40273-018-0620-y",

language = "English",

volume = "36",

pages = "381--382",

journal = "Pharmacoeconomics (Print)",

issn = "1170-7690",

publisher = "Adis",

number = "3",

}

Response to 'Comment on ''Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy"'. / Ansaripour, Amir; Uyl - de Groot, Carin ; Redekop, Ken.
In: Pharmacoeconomics (Print), Vol. 36, No. 3, 2018, p. 381-382.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Response to 'Comment on ''Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy"'

AU - Ansaripour, Amir

AU - Uyl - de Groot, Carin

AU - Redekop, Ken

PY - 2018

Y1 - 2018

U2 - 10.1007/s40273-018-0620-y

DO - 10.1007/s40273-018-0620-y

M3 - Article

C2 - 29427071

SN - 1170-7690

VL - 36

SP - 381

EP - 382

JO - Pharmacoeconomics (Print)

JF - Pharmacoeconomics (Print)

IS - 3

ER -